Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 16/20 | 0.72 |
| ▸ | ROCK1 | Q13464 | 16/20 | 0.72 |
| ▸ | CDC42BPA | Q5VT25 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18254789 | 0.90 | ROCK2 (0.66) | ROCK2ROCK1CDC42BPACYP2C9MAPK10 | |
| SCHEMBL18254786 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL1648507 | 0.82 | ROCK2 (1.00) | ROCK2ROCK1CDC42BPACYP2C9 | |
| SCHEMBL21376251 | 0.81 | ROCK2 (0.59) | ROCK2ROCK1CDC42BPACYP2C9MAPK10 | |
| SCHEMBL21909056 | 0.79 | ROCK2 (0.52) | ROCK2ROCK1CDC42BPACYP2C9MAPK10 | |
| SCHEMBL13457090 | 0.78 | ROCK2 (1.00) | ROCK2ROCK1CDC42BPACYP2C9MAPK10 | |
| SCHEMBL1649561 | 0.77 | ROCK2 (1.00) | ROCK2ROCK1CDC42BPACYP2C9 | |
| SCHEMBL18254798 | 0.76 | ROCK1 (0.64) | ROCK2ROCK1CDC42BPACYP2C9MAPK10 | |
| SCHEMBL21376141 | 0.76 | ROCK1 (0.69) | ROCK2ROCK1 | |
| SCHEMBL20181637 | 0.76 | ROCK1 (0.69) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC | 2019-09-19 | — | — | US | disclosed |
| WO-2018094362-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | TRANSLATIONAL DRUG DEVELOPMENT, LLC (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10807966-B2 | Heterocyclic compounds as kinase inhibitors | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885CDC42BPA 464/4885 |
| US-20190284157-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | ROCK2 76/4885ROCK1 67/4885CDC42BPA 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.